These recent studies have indeed shown positive results in lung cancer patients, especially in adenocarcinoma patients treated with EGFR-TKI-targeted therapy, so that prognostication studies based on genetic mutations for this treatment need to be carried out, especially in Indonesia with a diverse population.7,35,36 In connection with standardized lung cancer prognostication studies based on management such as tyrosine kinase inhibitors which are also reviewed based on genetic mutations, will be carried out in future studies. The gene discussed is EGFR; the disease is lung cancer.